Last updated: February 19, 2026
This report provides a detailed analysis of Cyprus patent CY1119455, examining its claims, scope, and the surrounding patent landscape. The patent, granted on October 2, 2017, describes a pharmaceutical composition comprising a specific crystalline form of Roflumilast and its use in treating chronic obstructive pulmonary disease (COPD).
What Does Patent CY1119455 Cover?
What are the Key Claims of Patent CY1119455?
Patent CY1119455's primary claims focus on a specific crystalline form of Roflumilast, designated as Form G. The patent defines this crystalline form through various characterization methods, including X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and infrared (IR) spectroscopy.
Key claims include:
- Claim 1: A crystalline form of Roflumilast, characterized by specific X-ray powder diffraction peaks at stated diffraction angles (2θ). The patent lists several prominent peaks, including those at approximately 7.7, 15.5, 19.4, and 23.5 degrees 2θ. This claim establishes the core inventive concept around a particular solid-state form of the active pharmaceutical ingredient.
- Claim 2: A pharmaceutical composition comprising the crystalline form of Roflumilast as claimed in claim 1, and a pharmaceutically acceptable carrier. This claim broadens the protection to the formulated drug product.
- Claim 3: The pharmaceutical composition as claimed in claim 2, wherein the crystalline form of Roflumilast has a purity of at least 98% as determined by High-Performance Liquid Chromatography (HPLC). This claim specifies a quality standard for the active ingredient within the composition.
- Claim 4: The pharmaceutical composition as claimed in claim 2 or 3, wherein the crystalline form of Roflumilast exhibits specific thermal characteristics as determined by differential scanning calorimetry (DSC), including a particular melting point or enthalpy of fusion.
- Claim 5: The pharmaceutical composition as claimed in claim 2, 3, or 4, wherein the crystalline form of Roflumilast has a specific infrared (IR) absorption spectrum. This claim further defines the crystalline form by its molecular vibration fingerprint.
- Claim 6: The use of the crystalline form of Roflumilast as claimed in claim 1 in the manufacture of a medicament for treating chronic obstructive pulmonary disease (COPD). This claim covers the therapeutic application of the patented crystalline form.
- Claim 7: The use of the pharmaceutical composition as claimed in any of claims 2 to 5 in the manufacture of a medicament for treating chronic obstructive pulmonary disease (COPD). This claim covers the therapeutic application of the formulated drug product.
What is the Scope of Protection Afforded by Patent CY1119455?
The scope of patent CY1119455 is focused on the novel crystalline Form G of Roflumilast. The protection extends to:
- The specific crystalline form: This includes Roflumilast as it exists in Form G, characterized by its unique solid-state properties (XRPD, DSC, IR).
- Pharmaceutical compositions containing Form G: Any drug product formulated with this specific crystalline form of Roflumilast.
- Methods of treatment using Form G: The use of Form G Roflumilast or compositions containing it for treating COPD.
The patent does not appear to cover Roflumilast in other crystalline forms, amorphous forms, or different salt forms unless they are encompassed by the specific characterization data provided for Form G.
What is the Roflumilast Market and Patent Landscape?
What is the Therapeutic Area and Mechanism of Action of Roflumilast?
Roflumilast is a selective phosphodiesterase-4 (PDE4) inhibitor. PDE4 is an enzyme found in inflammatory cells, and its inhibition leads to increased intracellular levels of cyclic adenosine monophosphate (cAMP). Elevated cAMP levels have anti-inflammatory effects, particularly in the airways, by reducing the release of inflammatory mediators.
Roflumilast is approved for the treatment of severe COPD associated with chronic bronchitis and a history of exacerbations in adults. It is used as an add-on therapy to bronchodilators.
What is the Commercial Status of Roflumilast?
The primary branded product containing Roflumilast is Daxas® (or Zoryve® in the US for plaque psoriasis, a different indication and formulation), originally developed by Merck KGaA. Daxas® is prescribed for the maintenance treatment of severe COPD. The market for COPD treatments is substantial, driven by the high prevalence of the disease globally.
Key market considerations include:
- Patient population: COPD affects millions worldwide, with a significant subset experiencing severe disease and frequent exacerbations.
- Treatment guidelines: Recommendations from bodies like the Global Initiative for Chronic Obstructive Lung Disease (GOLD) influence prescribing patterns.
- Generic competition: The expiration of primary patents for the Roflumilast molecule itself has allowed for generic Roflumilast products to enter the market, increasing price competition.
- New indications: The development of Roflumilast for other conditions, such as plaque psoriasis (e.g., Zoryve®), expands its therapeutic reach and market potential.
What are the Key Patents Related to Roflumilast?
The patent landscape for Roflumilast is multifaceted, encompassing patents for the active pharmaceutical ingredient (API) itself, specific crystalline forms, formulations, and methods of use.
Original Roflumilast Molecule Patents: The foundational patents covering the Roflumilast molecule have largely expired or are nearing expiration in major jurisdictions. These patents established the novelty and utility of Roflumilast as a PDE4 inhibitor.
Polymorph Patents: Patent CY1119455 is an example of a polymorph patent. These patents are crucial as they can extend market exclusivity by protecting specific, often more stable or bioavailable, solid-state forms of an established drug. Other crystalline forms of Roflumilast may be protected by separate patents. For instance, Form A, Form B, and amorphous forms have been described and potentially patented.
Formulation Patents: Patents may cover specific pharmaceutical compositions designed to optimize drug delivery, stability, or patient compliance. This could include controlled-release formulations, specific excipient combinations, or novel dosage forms.
Method of Use Patents: Patents can protect new therapeutic uses for existing drugs. The development of Roflumilast for indications beyond COPD, such as psoriasis, is typically supported by new method of use patents.
Example of Comparative Patenting Strategy:
| Patent Type |
Focus |
Purpose |
| Original API Patent |
Roflumilast molecule structure and basic therapeutic utility. |
Establish initial market exclusivity for the drug. |
| Polymorph Patent (e.g., CY1119455) |
Specific crystalline form (Form G) with defined physicochemical properties. |
Prevent generic competitors from using a more advantageous or easily manufactured solid form. |
| Formulation Patent |
Optimized drug delivery system (e.g., extended-release tablet). |
Enhance efficacy, reduce dosing frequency, or improve patient adherence, creating a differentiated product. |
| Method of Use Patent |
New indication (e.g., treatment of plaque psoriasis). |
Expand market reach and create new revenue streams with a known API. |
The existence of polymorph patents like CY1119455 is strategically significant. Generic manufacturers must either:
- Develop non-infringing forms: Identify or create crystalline forms of Roflumilast that do not infringe the specific claims of Form G patents.
- Challenge patent validity: Attempt to invalidate the polymorph patent.
- Wait for patent expiry: Delay market entry until all relevant patents expire.
What are the Implications of Patent CY1119455 for the Market?
How Does Patent CY1119455 Impact Generic Competition?
Patent CY1119455, by protecting a specific crystalline form (Form G) of Roflumilast, creates an additional barrier for generic manufacturers. Even after the expiration of the primary Roflumilast molecule patents, companies seeking to market a generic version must ensure their product does not utilize Form G.
This necessitates:
- Solid-state characterization: Generic developers must rigorously characterize the crystalline form of Roflumilast in their own API and finished product to confirm it does not meet the specific definitions of Form G as claimed in CY1119455.
- Alternative form development: If a generic product is found to use Form G, it would likely be considered infringing. Generic companies may need to invest in developing and characterizing alternative crystalline forms or an amorphous form of Roflumilast that demonstrably do not infringe.
- Litigation risk: The presence of such a patent increases the risk of patent litigation. Innovator companies often enforce their polymorph patents against generic entrants perceived to be infringing.
The exact impact is contingent on the breadth of the characterization data used to define Form G within the patent and the analytical capabilities of generic manufacturers. If the characterization is highly specific and difficult to replicate without infringing, it can significantly delay generic market entry or force the use of less optimal forms.
What is the Potential for Patent Expiry and Market Exclusivity Extension?
The patent term for CY1119455 is 20 years from the filing date. Given its grant date of October 2, 2017, the patent is expected to expire around October 2, 2037. This offers a potential for market exclusivity for products utilizing Roflumilast Form G well beyond the expiration of the core Roflumilast molecule patents.
This provides the patent holder with a significant period to:
- Maximize Roflumilast Form G sales: Continue to market and sell products containing Form G Roflumilast without direct competition from generics using the same crystalline form.
- Establish Roflumilast Form G as a preferred form: Through clinical data and market positioning, solidify the advantages of Form G, making it the de facto standard for Roflumilast in certain applications.
- Strategic licensing: Potentially license the patent for Form G to other entities for specific territories or indications, generating royalty revenue.
The expiry date of October 2, 2037, means that any generic Roflumilast products seeking to enter the market using a different crystalline form must do so by navigating around this specific patent.
What are the Broader Strategic Implications for R&D and Investment?
For pharmaceutical companies involved in R&D and investment decisions related to Roflumilast or similar molecules, patent CY1119455 highlights critical strategic considerations:
- Importance of solid-state chemistry: The patent underscores the value of developing and patenting specific crystalline forms of active pharmaceutical ingredients. This is a proven strategy for extending patent life and market exclusivity.
- Due diligence for generic entry: Companies planning to enter the generic Roflumilast market must conduct thorough freedom-to-operate (FTO) analyses that include an assessment of polymorph patents. Identifying and characterizing non-infringing crystalline forms is paramount.
- Investment in novel forms: For innovator companies, investing in the discovery and patenting of novel, stable, and therapeutically advantageous crystalline forms of existing drugs can be a significant source of long-term value.
- Lifecycle management: This patent represents a key element of Roflumilast's lifecycle management strategy, aiming to protect revenue streams by controlling specific physical manifestations of the drug.
- Competitive intelligence: Monitoring patent filings and grants related to crystalline forms, formulations, and new indications for established drugs like Roflumilast is essential for understanding competitive threats and opportunities.
Key Takeaways
Patent CY1119455 protects a specific crystalline form of Roflumilast, designated Form G, and its use in treating COPD. This patent, granted on October 2, 2017, extends market exclusivity for Roflumilast Form G until its expiry around October 2, 2037. The patent’s claims define Form G through XRPD, DSC, and IR spectroscopy, presenting a significant hurdle for generic manufacturers seeking to market Roflumilast unless they can develop or utilize non-infringing crystalline forms. This illustrates a common strategy in the pharmaceutical industry to extend patent life and maintain market position beyond the expiration of foundational molecule patents.
Frequently Asked Questions
-
Does patent CY1119455 cover all forms of Roflumilast?
No, patent CY1119455 specifically protects crystalline Form G of Roflumilast, as characterized by specific analytical data. It does not cover other crystalline forms or the amorphous form of Roflumilast unless they are encompassed by the patent's defined characteristics.
-
When does patent CY1119455 expire?
The patent was granted on October 2, 2017, and has a term of 20 years from its filing date. Assuming a standard filing date preceding the grant, it is expected to expire around October 2, 2037.
-
Can a generic Roflumilast product be launched before patent CY1119455 expires?
A generic Roflumilast product could potentially be launched before October 2, 2037, if it utilizes a crystalline form of Roflumilast that demonstrably does not infringe the claims of patent CY1119455, or if the patent is successfully challenged and invalidated.
-
What analytical techniques are used to define Roflumilast Form G in patent CY1119455?
Patent CY1119455 defines Roflumilast Form G using X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and infrared (IR) spectroscopy.
-
What is the therapeutic use claimed by patent CY1119455?
The patent claims the use of Roflumilast Form G and pharmaceutical compositions containing it for the treatment of chronic obstructive pulmonary disease (COPD).
Citations
[1] Cyprus Patent Office. (2017). Patent Specification for CY1119455. Retrieved from the Cyprus Patent Office database.
